17.59 -0.04 (-0.25%)
After hours: 4:26PM EDT
|Bid||17.62 x 900|
|Ask||17.63 x 2200|
|Day's Range||17.36 - 17.64|
|52 Week Range||15.50 - 21.61|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||21.73|
|Forward Dividend & Yield||0.83 (4.84%)|
|1y Target Est||23.76|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million. The sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan's biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda.
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
(Bloomberg) -- Takeda Pharmaceutical Co. is nearing the sale of a portfolio of assets in the Middle East, Africa and Russia to separate buyout firms that could help the drugmaker raise about $1 billion to reduce debt, according to people familiar with the matter.The Japanese company is in advanced talks to sell over-the-counter and prescription-drug assets in Russia to Stada Arzneimittel AG, the German pharmaceutical firm owned by Cinven and Bain Capital, the people said, asking not to be identified because the deliberations are private.It’s also close to reaching an agreement to sell its assets in the Middle East and Africa to Acino International AG, a Swiss company owned by Nordic Capital and Avista Capital Partners, they said.No final decision has been made and talks could still fall apart or face delays, the people said. Representatives for Takeda, Stada, Cinven, Bain, Nordic Capital and Avista declined to comment.Shares of Takeda rose 0.9% to close at 3,720 yen Friday in Tokyo.Takeda is also seeking to sell other over-the-counter and prescription-drug businesses in Latin America, Asia and western Europe, Bloomberg News reported last month.The drugmaker is aiming to raise about $10 billion of disposals, simplifying its portfolio and cutting debt after its $62 billion takeover of Shire Plc. The company is looking to divest non-core businesses outside Japan where the company isn’t an industry leader and doesn’t have critical mass in the market.In May, Takeda agreed to sell eye-disease medicines to Novartis AG for as much as $5.3 billion.(Updates with background on previous disposal in last paragraph)\--With assistance from Michael Hytha.To contact the reporters on this story: Manuel Baigorri in Hong Kong at firstname.lastname@example.org;Sarah Syed in London at email@example.comTo contact the editors responsible for this story: Fion Li at firstname.lastname@example.org, ;Dinesh Nair at email@example.com, Amy Thomson, Aaron KirchfeldFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.
The pace of acquisitions in the biotech industry is expected to accelerate as big pharma seeks to boost growth Continue reading...
(Bloomberg) -- Takeda Pharmaceutical Co. is close to selling some assets in emerging markets and western Europe, people familiar with the matter said, a move that would help the Japanese drugmaker reduce its debt pile.Takeda may announce a sale of over-the-counter and prescription drugs in Latin America, the Middle East, Africa, Russia and Asia as early as in the coming weeks, the people said, asking not to be identified because the matter is private. A sale of the drugs, which Takeda acquired through its 2011 purchase of Swiss rival Nycomed, could fetch about $3 billion in total, Bloomberg News first reported in January.The company may decide to sell the products to different buyers by geography, the people said. Acino International AG, backed by buyout firms Nordic Capital and Avista Capital Partners, and Stada Arzneimittel AG, owned by Cinven and Bain Capital, are among bidders for different assets, the people said. Other companies that have shown an interest in some of the assets include Brazil’s EMS SA and Uniao Quimica Farmaceutica Nacional SA, the people said.A separate sale by Takeda of OTC and prescription medicines in Western Europe has drawn interest from private-equity firms such as Advent International, which owns drugmaker Zentiva, as well as Apollo Global Management Inc. and Cerberus Capital Management, the people said. The assets could be valued at about 1 billion euros ($1.1 billion), people familiar with the matter said in October.The asset sales would help Takeda reduce debt and simplify its portfolio after its $62 billion takeover of Shire Plc. The Tokyo-based company wants to offload all assets not core to its focus on gastroenterology, oncology, neuroscience, rare diseases and plasma-derived therapies, and has set a target of $10 billion worth of divestment altogether.In May, Takeda agreed to sell eye-disease medicines to Novartis AG for as much as $5.3 billion. The drugmaker said in July that it is confident it can cut its debt to two times earnings before interest, tax, depreciation and amortization in three to five years.Deliberations are ongoing, and other bidders could still emerge, the people said. Representatives for Takeda, Advent, Apollo, Cerberus, Stada, Acino, EMS and Uniao Quimica declined to comment. (Updates with Uniao Quimica interest in third paragraph.)\--With assistance from Tim Loh, Sarah Syed, Fabiola Moura, Kati Pohjanpalo, Lisa Du and Rachel Chang.To contact the reporters on this story: Manuel Baigorri in Hong Kong at firstname.lastname@example.org;Dinesh Nair in London at email@example.com;Cristiane Lucchesi in Sao Paulo at firstname.lastname@example.orgTo contact the editors responsible for this story: Fion Li at email@example.com, Ville Heiskanen, Ben ScentFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...
− Early proof of concept study showed TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo
Takeda Pharmaceutical Company Limited today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective
– From the results of a Phase 2 study, maribavir, an investigational agent that targets a specific CMV protein, may result in the clearance of CMV infections, a condition with pote
OSAKA, Japan-- -- Also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year Achieved more than double the average pharmaceutical industry sustainability score Demonstrated significant year-over-year growth in score for strategy to improve access to medicines Takeda Pharmaceutical Company Limited today announced that it has been named in the 2019 Dow Jones Sustainability ...
− Takeda UK Ltd. is pleased to announce that NICE has recommended the use of Takhzyro® ▼ (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema ...
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure ...
OSAKA, Japan, Sept. 6, 2019 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effective immediately due to a potential issue related to rubber particulates originating from the rubber septum of the NATPARA cartridge. During the 14-day NATPARA treatment period, the septum is punctured by a needle each day to obtain the daily dosage of NATPARA solution.